Accelerate FDA & Regulatory Clearance with Full-Service Medical Device Cybersecurity

Medical device cybersecurity, explained

Medical device cybersecurity is the discipline of designing, building, and maintaining a medical device so it remains safe and effective, even when it is exposed to real-world misuse, malicious activity, and software supply chain risk.

This is not generic IT security. Medical device cybersecurity focuses on the device system as it actually operates: hospital networks, patient homes, clinician workflows, companion apps, cloud services, update servers, and third-party software components. A device can be technically “working” and still be unsafe if a cybersecurity issue can change its behavior, delay therapy, expose sensitive data, or prevent clinicians from using it when they need it.

Why it matters for FDA submissions

The FDA’s current cybersecurity guidance makes the expectation clear: cybersecurity is part of device safety and effectiveness, and sponsors should provide evidence that cybersecurity has been addressed throughout the product lifecycle. The most recent version was issued on February 3, 2026, and it addresses the FDA’s recommendations related to Section 524B (“cyber devices”).

In plain terms, FDA reviewers are typically looking for three things:

• Security risk management you can trace: a clear chain from realistic threats and hazards to security controls and test evidence, not just high-level statements.
• Architecture and design that match the real environment: data flows, trust boundaries, interfaces, and dependencies that reflect how the device system is used.
• Postmarket readiness: plans and processes to monitor, receive, and respond to vulnerabilities after launch.

Authoritative references: FDA premarket cybersecurity guidance (Feb 3, 2026), FDA postmarket cybersecurity guidance (Dec 2016), and IMDRF Principles and Practices for Medical Device Cybersecurity (N60).

What “cyber risk” looks like in the real world

Cybersecurity issues in healthcare are not hypothetical. Ransomware, for example, is designed to encrypt files and make systems unusable, which can cascade into downtime across clinical environments.

(Reference: CISA Ransomware 101.)

For device manufacturers, practical risk commonly shows up as:

• Unauthorized changes to therapy parameters, alarms, or clinical workflows
• Inability to update or patch safely once devices are deployed
• Exploitable third-party components and unclear software inventories
• Weak authentication, insecure interfaces, or insufficient logging for detection and response
• “Paper compliance” that does not map to the actual device architecture and intended use

What The FDA expects, in practical terms

Cybersecurity packages fail review most often for one reason: the evidence is incomplete, inconsistent, or not packaged in a way that makes it easy to verify. We focus on producing the deliverables reviewers actually use to assess cybersecurity.

Typical deliverables that reviewers expect to see

• Device system definition and architecture views: data flows, interfaces, trust boundaries, and dependencies (including cloud and mobile components where applicable).
• Threat modeling and security risk assessment: realistic abuse cases tied to safety and effectiveness impacts, with mitigations and residual risk decisions documented.
• Security controls rationale: what controls exist, where they are implemented, and why they are appropriate for the device system and use environment.
• Cybersecurity testing evidence: vulnerability assessment and penetration testing results with remediation and retest evidence.
• SBOM strategy and outputs: a clear inventory of software components and a plan to maintain and monitor it over the device lifecycle.
• Postmarket cybersecurity plan: how you will receive, assess, and address vulnerabilities and communicate updates.

If you need these deliverables packaged for submission, start here: FDA premarket cybersecurity services. If you are already in review and received questions or a deficiency, see: FDA cybersecurity deficiency response.